Atlas Trials

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

Clinical trial NCT03527108 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03527108
Sponsor
Fox Chase Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2020-10-08
Primary completion
2026-12-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.